Horizon Pharma (HZNP) Stock Tanks on Mixed Earnings

NEW YORK (TheStreet) -- Horizon Pharma (HZNP) closed trading down 6.02% to $27.62 on Friday after the pharmaceutical company released its first-quarter earnings results before the opening bell today.

The company reported a first-quarter net loss of $19.6 million, or 21 cents per share on an adjusted basis, missing analysts' consensus estimates of 23 cents per share by 2 cents. Revenue for the period rose 118% to $113.1 million, topping analysts estimates of $103.7 million.

The company also issued full-year revenue guidance between $590 million and $610 million, well above analysts' $539 million expectations for the year.

Separately, the company announced that it settled patent infringement litigation with generic drug maker Perrigo (PRGO) that grants Perrigo non-exclusive rights to market a generic version of Horizon's arthritis ointment, Pennsaid, in the U.S.

Horizon shares are up 0.36% to $27.72 in after-hours trading today.

HZNP Chart HZNP data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

More from Markets

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

NYSE Trader Expects Blowout Earnings From Alphabet, Amazon and Facebook

Don't Panic! The Risk of a Recession This Year Is Low

Don't Panic! The Risk of a Recession This Year Is Low